323 related articles for article (PubMed ID: 34481962)
21. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
Scheen AJ
Diabetes Metab; 2022 Mar; 48(2):101325. PubMed ID: 35121148
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.
Aldafas R; Crabtree T; Alkharaiji M; Vinogradova Y; Idris I
Age Ageing; 2024 Jan; 53(1):. PubMed ID: 38287703
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
25. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
26. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
27. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
28. Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Wong Y; Cheung CL
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1719-e1726. PubMed ID: 34748021
[TBL] [Abstract][Full Text] [Related]
29. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
31. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
Paquot N; Scheen AJ
Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Barnett AH; Charbonnel B; Moses RG; Kalra S
Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
[TBL] [Abstract][Full Text] [Related]
33. Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.
Wu MZ; Teng TK; Tsang CT; Chan YH; Lee CH; Ren QW; Huang JY; Cheang IF; Tse YK; Li XL; Xu X; Tse HF; Lam CSP; Yiu KH
Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):45-52. PubMed ID: 37942588
[TBL] [Abstract][Full Text] [Related]
34. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zhang F; Xu S; Tang L; Pan X; Tong N
Front Endocrinol (Lausanne); 2020; 11():288. PubMed ID: 32582019
[No Abstract] [Full Text] [Related]
35. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
36. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
37. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.
Kaku K; Kisanuki K; Shibata M; Oohira T
Drug Saf; 2019 Nov; 42(11):1311-1327. PubMed ID: 31654243
[TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Li D; Shi W; Wang T; Tang H
Diabetes Obes Metab; 2018 Aug; 20(8):1972-1976. PubMed ID: 29573110
[TBL] [Abstract][Full Text] [Related]
39. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
[TBL] [Abstract][Full Text] [Related]
40. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Ĺopuch S
Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]